Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 1.5% – Time to Sell?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) was down 1.5% during trading on Tuesday . The stock traded as low as $6.65 and last traded at $6.66. Approximately 494,945 shares changed hands during mid-day trading, a decline of 91% from the average daily volume of 5,738,237 shares. The stock had previously closed at $6.76.

Wall Street Analysts Forecast Growth

RXRX has been the subject of several analyst reports. Leerink Partners reduced their price objective on shares of Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating for the company in a research note on Tuesday, September 3rd. Needham & Company LLC cut their target price on Recursion Pharmaceuticals from $16.00 to $11.00 and set a “buy” rating on the stock in a report on Wednesday, September 4th. KeyCorp decreased their price target on Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating for the company in a research note on Thursday, July 11th. Finally, Jefferies Financial Group cut their price objective on Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating on the stock in a research note on Tuesday, September 3rd. Four analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $9.40.

Recursion Pharmaceuticals Trading Down 4.2 %

The company has a quick ratio of 6.07, a current ratio of 6.07 and a debt-to-equity ratio of 0.04. The company has a 50-day moving average price of $6.73 and a 200-day moving average price of $7.74. The company has a market capitalization of $1.50 billion, a price-to-earnings ratio of -3.96 and a beta of 0.80.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its earnings results on Thursday, August 8th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.05). The business had revenue of $14.42 million during the quarter, compared to analyst estimates of $11.96 million. Recursion Pharmaceuticals had a negative net margin of 755.37% and a negative return on equity of 79.47%. The business’s quarterly revenue was up 30.9% compared to the same quarter last year. During the same period last year, the business earned ($0.38) EPS. Research analysts predict that Recursion Pharmaceuticals, Inc. will post -1.58 EPS for the current fiscal year.

Insider Transactions at Recursion Pharmaceuticals

In related news, Director Blake Borgeson sold 11,447 shares of the stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $6.82, for a total value of $78,068.54. Following the completion of the sale, the director now owns 7,144,216 shares in the company, valued at approximately $48,723,553.12. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, Director Blake Borgeson sold 11,447 shares of the firm’s stock in a transaction on Tuesday, August 6th. The stock was sold at an average price of $6.82, for a total value of $78,068.54. Following the completion of the transaction, the director now directly owns 7,144,216 shares of the company’s stock, valued at $48,723,553.12. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Christopher Gibson sold 30,000 shares of Recursion Pharmaceuticals stock in a transaction on Wednesday, August 7th. The stock was sold at an average price of $7.10, for a total transaction of $213,000.00. Following the sale, the chief executive officer now owns 758,738 shares in the company, valued at $5,387,039.80. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 195,682 shares of company stock worth $1,284,153. 15.75% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Recursion Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in RXRX. Perceptive Advisors LLC bought a new position in shares of Recursion Pharmaceuticals during the 2nd quarter worth approximately $5,769,000. Capstone Investment Advisors LLC acquired a new stake in shares of Recursion Pharmaceuticals in the 1st quarter valued at $161,000. Benjamin F. Edwards & Company Inc. boosted its stake in shares of Recursion Pharmaceuticals by 6,439.6% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 169,900 shares of the company’s stock valued at $1,274,000 after purchasing an additional 167,302 shares in the last quarter. Scientech Research LLC acquired a new stake in shares of Recursion Pharmaceuticals during the 2nd quarter worth about $1,052,000. Finally, Ghisallo Capital Management LLC bought a new position in Recursion Pharmaceuticals during the 2nd quarter valued at about $8,250,000. 89.06% of the stock is owned by institutional investors and hedge funds.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.